

A possibility as new tumor marker; Assay of soluble VEGFR-3/Flt-4 in blood

VEGFR-3/Flt-4



■ VEGFR-3/Flt-4 Kit

Code No.	Name	Volume	Assay Range	Incubation Time	Application
27779	Human VEGFR-3/Flt-4 Assay Kit - IBL	96 Well	0.03 ~ 2 ng/mL	1st incubation, 37°C, 1hr 2nd incubation, 4°C, 30min	EDTA-Plasma, Serum Cell culture supernatant

All members of the VEGF family (VEGF-A, -B, -C, -D, -E) stimulate cellular responses by binding to tyrosine kinase receptors (the VEGFRs) on the cell surface, causing them to dimerize and become activated through transphosphorylation. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. The VEGFR-3, which is also known as Flt-4 (Fms-like tyrosine kinase 4), has been discovered as a third receptor. It is known that VEGFR-3/Flt-4 mediates lymphangiogenesis in response to VEGF-C and VEGF-D. This product is capable of the determination of human VEGFR-3/Flt-4 in human serum, EDTA-plasma or cell culture supernatant.

- High sensitivity: Assay range 0.03 ~ 2 ng/mL, Sensitivity, 0.004 ng/mL
- VEGFR-3/Flt-4 in blood is comparatively stable. 80% or more of recovery is shown after it was kept at 37°C overnight.
- The reference value in blood of healthy individuals is 40 ~ 80 ng/mL.
- Serum or plasma samples should be diluted 100 times or more before measuring. Please note that when the specimen includes the protein in high concentration, it needs further dilution.

Specificity



The following studies have been reported, but the data of them are not by this ELISA kit.

1. Brian I et.al. Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. *J Clin Oncol.* 2008 Aug 1;26(22):3743-8.
2. Roger Mouawada et.al. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: Correlation with clinical parameters and outcome. *Eur J Cancer.* 2009 Jan 19.

Manufacturer :

Immuno-Biological Laboratories Co., Ltd.

5-1 Aramachi, Takasaki-shi, Gunma 370-0831, JAPAN
 TEL: 027-310-8040
 FAX: 027-310-8045
 E-mail: do-ibl@ibl-japan.co.jp
 URL: <http://www.ibl-japan.co.jp>

